The Telangana government has unveiled an ambitious strategy to position Hyderabad as a leading global drug discovery and pharmaceutical innovation hub, leveraging the city’s established strengths in pharmaceuticals, biotechnology, research and life sciences. The proposed initiative aims to create an integrated ecosystem that supports the entire value chain of drug development, from early stage research and discovery to clinical development, manufacturing and commercialization.

The roadmap is being developed in collaboration with industry stakeholders, academic institutions and technology organizations, including Nasscom, with the objective of accelerating pharmaceutical innovation and attracting global investments in healthcare and life sciences. The initiative is expected to strengthen Hyderabad’s position as one of the world’s most important pharmaceutical and biotechnology destinations.

According to state officials, the proposed ecosystem will focus on fostering collaboration among pharmaceutical companies, biotechnology firms, contract research organizations (CROs), startups, venture capital investors, academic institutions and technology providers. The initiative aims to reduce barriers to innovation while creating a robust environment for the discovery and development of next generation therapeutics.

Hyderabad has long been recognized as one of India’s largest pharmaceutical and life sciences clusters. The city contributes significantly to India’s pharmaceutical exports and is home to Genome Valley, the country’s first and largest organized life sciences cluster. Spread across more than 2,000 acres, Genome Valley hosts over 200 life sciences companies, including global pharmaceutical manufacturers, biotechnology companies, vaccine developers, research institutions and healthcare technology firms.

The city also plays a critical role in global healthcare supply chains. Telangana contributes approximately one third of the world’s vaccine production, while Hyderabad remains a major hub for generic medicines, Active Pharmaceutical Ingredients (APIs), biologics and contract research services. Several leading global and Indian pharmaceutical companies operate research, manufacturing and innovation centers in the region.

The proposed strategy aligns with Telangana’s broader ambition to move beyond pharmaceutical manufacturing and establish itself as a center for scientific discovery and innovation. Key focus areas are expected to include drug discovery, biologics, precision medicine, artificial intelligence in healthcare, computational biology, clinical research and advanced therapeutics.

Industry experts estimate that the global drug discovery market could exceed USD 140 billion by 2030, driven by advances in artificial intelligence, genomics, biologics and precision medicine. They believe that Hyderabad’s combination of scientific talent, manufacturing expertise, research infrastructure and supportive policy environment provides a strong foundation for becoming a globally competitive drug discovery ecosystem.

Healthcare and biotechnology leaders have welcomed the initiative, emphasizing that India must increasingly focus on innovation led growth, intellectual property generation and translational research to strengthen its position in the global pharmaceutical industry. Experts also note that creating integrated ecosystems that bring together academia, industry and investors will be critical for accelerating the development of novel therapies.

The Telangana government’s latest initiative underscores its commitment to transforming Hyderabad from a global pharmaceutical manufacturing powerhouse into a leading international destination for drug discovery, biotechnology innovation and next generation healthcare research.